Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2186
mi
from 91732
Orlando, FL
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2186
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2186
mi
from 91732
Ormond Beach, FL
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2186
mi
from 91732
Ormond Beach, FL
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1509
mi
from 91732
Minneapolis, MN
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1502
mi
from 91732
Plymouth, MN
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1502
mi
from 91732
Plymouth, MN
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2184
mi
from 91732
Charleston, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2007
mi
from 91732
Easley, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2007
mi
from 91732
Easley, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2094
mi
from 91732
Rock Hill, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2094
mi
from 91732
Rock Hill, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1989
mi
from 91732
Seneca, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1989
mi
from 91732
Seneca, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2269
mi
from 91732
Richmond, VA
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2188
mi
from 91732
Mount Pleasant, SC
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2188
mi
from 91732
Mount Pleasant, SC
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2301
mi
from 91732
Baltimore, MD
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1570
mi
from 91732
Saint Louis, MO
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
628
mi
from 91732
Medford, OR
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
628
mi
from 91732
Medford, OR
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2008
mi
from 91732
Anderson, SC
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2008
mi
from 91732
Anderson, SC
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2315
mi
from 91732
Hialeah, FL
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2315
mi
from 91732
Hialeah, FL
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
5790
mi
from 91732
Ruedersdorf,
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
5790
mi
from 91732
Ruedersdorf,
Click here to add this to my saved trials
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2028
mi
from 91732
Simpsonville, SC
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2028
mi
from 91732
Simpsonville, SC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
427
mi
from 91732
Tucson, AZ
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
31
mi
from 91732
Newport Beach, CA
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
31
mi
from 91732
Newport Beach, CA
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
37
mi
from 91732
Riverside, CA
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
37
mi
from 91732
Riverside, CA
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2177
mi
from 91732
DeLand, FL
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2177
mi
from 91732
DeLand, FL
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
942
mi
from 91732
Coeur d'Alene, ID
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
942
mi
from 91732
Coeur d'Alene, ID
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2100
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
628
mi
from 91732
Medford, OR
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
628
mi
from 91732
Medford, OR
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2184
mi
from 91732
Charleston, SC
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2007
mi
from 91732
Easley, SC
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2007
mi
from 91732
Easley, SC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1989
mi
from 91732
Seneca, SC
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1989
mi
from 91732
Seneca, SC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2322
mi
from 91732
Newport News, VA
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2322
mi
from 91732
Newport News, VA
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
952
mi
from 91732
Renton, WA
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
952
mi
from 91732
Renton, WA
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from 91732
Temuco,
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from 91732
Temuco,
Click here to add this to my saved trials
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1570
mi
from 91732
Saint Louis, MO
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
343
mi
from 91732
Phoenix, AZ
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2515
mi
from 91732
Lebanon, NH
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2515
mi
from 91732
Lebanon, NH
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2438
mi
from 91732
Albany, NY
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2438
mi
from 91732
Albany, NY
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1965
mi
from 91732
Columbus, OH
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1965
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
628
mi
from 91732
Medford, OR
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
628
mi
from 91732
Medford, OR
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2058
mi
from 91732
Gaffney, SC
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2058
mi
from 91732
Gaffney, SC
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2022
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2042
mi
from 91732
Spartanburg, SC
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2067
mi
from 91732
Union, SC
Click here to add this to my saved trials
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1360
mi
from 91732
Kingwood, TX
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1360
mi
from 91732
Kingwood, TX
Click here to add this to my saved trials